Nicole Massoll
Concepts (236)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Nodule | 5 | 2022 | 40 | 1.240 |
Why?
| Thyroid Neoplasms | 8 | 2022 | 161 | 1.150 |
Why?
| Biopsy, Fine-Needle | 6 | 2020 | 116 | 0.600 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 62 | 0.580 |
Why?
| Uterus | 2 | 2008 | 99 | 0.570 |
Why?
| Papillomavirus Infections | 2 | 2008 | 163 | 0.510 |
Why?
| Carcinoma, Papillary | 3 | 2017 | 65 | 0.490 |
Why?
| Breast Neoplasms | 7 | 2018 | 1248 | 0.410 |
Why?
| Vulvar Neoplasms | 3 | 2008 | 54 | 0.390 |
Why?
| Carcinoma, Squamous Cell | 4 | 2008 | 386 | 0.370 |
Why?
| Cysts | 2 | 2006 | 48 | 0.350 |
Why?
| MicroRNAs | 3 | 2022 | 387 | 0.340 |
Why?
| Uterine Cervical Neoplasms | 2 | 2008 | 276 | 0.320 |
Why?
| Uterine Cervical Dysplasia | 1 | 2008 | 51 | 0.320 |
Why?
| Precancerous Conditions | 1 | 2008 | 93 | 0.310 |
Why?
| Carcinoma, Lobular | 1 | 2007 | 32 | 0.300 |
Why?
| Cytological Techniques | 1 | 2006 | 14 | 0.290 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2007 | 96 | 0.280 |
Why?
| Adenomyoma | 1 | 2005 | 2 | 0.270 |
Why?
| Neoplasms, Hormone-Dependent | 1 | 2005 | 8 | 0.270 |
Why?
| Carcinoma in Situ | 2 | 2008 | 74 | 0.270 |
Why?
| Gynecologic Surgical Procedures | 1 | 2005 | 31 | 0.270 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 3 | 2010 | 20 | 0.270 |
Why?
| Uterine Neoplasms | 1 | 2005 | 63 | 0.260 |
Why?
| Biopsy, Needle | 1 | 2006 | 195 | 0.260 |
Why?
| Lymph Nodes | 3 | 2017 | 282 | 0.260 |
Why?
| Carcinoma, Medullary | 1 | 2004 | 15 | 0.250 |
Why?
| Mastectomy | 2 | 2018 | 143 | 0.220 |
Why?
| Humans | 32 | 2022 | 54132 | 0.210 |
Why?
| Focal Adhesion Kinase 1 | 2 | 2012 | 15 | 0.190 |
Why?
| Diagnostic Tests, Routine | 1 | 2020 | 32 | 0.190 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2020 | 27 | 0.190 |
Why?
| Female | 21 | 2020 | 28437 | 0.190 |
Why?
| Diagnosis, Differential | 4 | 2008 | 1133 | 0.190 |
Why?
| Mutation | 6 | 2022 | 1499 | 0.170 |
Why?
| DNA, Neoplasm | 2 | 2018 | 172 | 0.170 |
Why?
| Lung Neoplasms | 2 | 2015 | 631 | 0.170 |
Why?
| Protein Kinase Inhibitors | 2 | 2012 | 216 | 0.170 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 90 | 0.170 |
Why?
| Immunohistochemistry | 6 | 2015 | 1097 | 0.160 |
Why?
| Thyroid Gland | 3 | 2020 | 93 | 0.150 |
Why?
| Gene Silencing | 2 | 2008 | 127 | 0.150 |
Why?
| Middle Aged | 11 | 2020 | 13094 | 0.150 |
Why?
| Pancreatic Neoplasms | 2 | 2010 | 235 | 0.150 |
Why?
| Neoplasm Invasiveness | 5 | 2015 | 294 | 0.140 |
Why?
| DNA, Viral | 2 | 2008 | 142 | 0.140 |
Why?
| Pathology | 2 | 2006 | 43 | 0.140 |
Why?
| Sensitivity and Specificity | 4 | 2020 | 925 | 0.140 |
Why?
| Pulmonary Medicine | 1 | 2015 | 15 | 0.140 |
Why?
| PTEN Phosphohydrolase | 1 | 2016 | 61 | 0.140 |
Why?
| Cytodiagnosis | 1 | 2015 | 42 | 0.140 |
Why?
| Fibroblasts | 2 | 2016 | 386 | 0.130 |
Why?
| Adult | 10 | 2020 | 14196 | 0.130 |
Why?
| Endosonography | 1 | 2015 | 97 | 0.130 |
Why?
| Cell Proliferation | 4 | 2016 | 1099 | 0.130 |
Why?
| Aged, 80 and over | 6 | 2020 | 3442 | 0.130 |
Why?
| Granuloma | 2 | 2007 | 46 | 0.120 |
Why?
| Lymphatic Metastasis | 3 | 2017 | 253 | 0.120 |
Why?
| Receptor, erbB-2 | 2 | 2018 | 79 | 0.110 |
Why?
| Laryngeal Diseases | 1 | 2013 | 14 | 0.110 |
Why?
| Laryngectomy | 1 | 2013 | 28 | 0.110 |
Why?
| Herpes Simplex | 1 | 2013 | 24 | 0.110 |
Why?
| Purine Nucleosides | 1 | 2012 | 3 | 0.110 |
Why?
| Receptor, IGF Type 1 | 1 | 2012 | 19 | 0.110 |
Why?
| Immunoenzyme Techniques | 2 | 2008 | 165 | 0.100 |
Why?
| Cell Movement | 2 | 2009 | 276 | 0.100 |
Why?
| Predictive Value of Tests | 2 | 2020 | 1053 | 0.090 |
Why?
| Receptors, Somatomedin | 1 | 2010 | 8 | 0.090 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 5 | 0.090 |
Why?
| Tissue Fixation | 2 | 2020 | 35 | 0.090 |
Why?
| Aniline Compounds | 1 | 2009 | 47 | 0.090 |
Why?
| Retrospective Studies | 5 | 2022 | 6387 | 0.080 |
Why?
| Melanoma | 1 | 2012 | 315 | 0.080 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 2 | 0.080 |
Why?
| Promoter Regions, Genetic | 2 | 2008 | 526 | 0.080 |
Why?
| Aged | 6 | 2020 | 10059 | 0.080 |
Why?
| Neuroblastoma | 1 | 2008 | 50 | 0.080 |
Why?
| Transglutaminases | 1 | 2008 | 17 | 0.080 |
Why?
| Mastitis | 1 | 2007 | 3 | 0.080 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2007 | 22 | 0.080 |
Why?
| GTP-Binding Proteins | 1 | 2008 | 95 | 0.080 |
Why?
| Genetic Markers | 1 | 2008 | 117 | 0.080 |
Why?
| Genes, erbB-2 | 1 | 2007 | 8 | 0.080 |
Why?
| Biopsy | 2 | 2007 | 694 | 0.080 |
Why?
| Prednisone | 1 | 2007 | 111 | 0.080 |
Why?
| Group Practice | 1 | 2006 | 4 | 0.070 |
Why?
| Cystatins | 1 | 2006 | 2 | 0.070 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 153 | 0.070 |
Why?
| Frozen Sections | 1 | 2006 | 16 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 209 | 0.070 |
Why?
| Cadherins | 1 | 2007 | 73 | 0.070 |
Why?
| Specialization | 1 | 2006 | 47 | 0.070 |
Why?
| Genomic Instability | 1 | 2007 | 95 | 0.070 |
Why?
| Colonic Neoplasms | 1 | 2008 | 165 | 0.070 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2008 | 251 | 0.070 |
Why?
| Medicine | 1 | 2006 | 55 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 682 | 0.070 |
Why?
| Polymerase Chain Reaction | 2 | 2005 | 533 | 0.070 |
Why?
| RNA, Small Interfering | 3 | 2012 | 254 | 0.070 |
Why?
| Nuclear Proteins | 1 | 2007 | 252 | 0.070 |
Why?
| Mullerian Ducts | 1 | 2005 | 4 | 0.070 |
Why?
| Fallopian Tubes | 1 | 2005 | 25 | 0.070 |
Why?
| Carrier Proteins | 1 | 2007 | 360 | 0.070 |
Why?
| Antigens, CD | 1 | 2007 | 242 | 0.070 |
Why?
| Medical Oncology | 1 | 2006 | 101 | 0.070 |
Why?
| Gene Expression | 1 | 2008 | 667 | 0.070 |
Why?
| ABO Blood-Group System | 1 | 2005 | 14 | 0.070 |
Why?
| Vulva | 1 | 2005 | 18 | 0.070 |
Why?
| Mice | 6 | 2017 | 6436 | 0.070 |
Why?
| Estrogen Replacement Therapy | 1 | 2005 | 41 | 0.070 |
Why?
| Ovariectomy | 1 | 2005 | 127 | 0.070 |
Why?
| Hysterectomy | 1 | 2005 | 89 | 0.070 |
Why?
| Signal Transduction | 1 | 2012 | 1754 | 0.070 |
Why?
| Data Collection | 1 | 2006 | 321 | 0.070 |
Why?
| Chromosome Aberrations | 1 | 2007 | 315 | 0.070 |
Why?
| Glucocorticoids | 1 | 2007 | 276 | 0.060 |
Why?
| Mice, Nude | 3 | 2010 | 284 | 0.060 |
Why?
| Carcinoma, Transitional Cell | 1 | 2005 | 53 | 0.060 |
Why?
| Regression Analysis | 1 | 2006 | 446 | 0.060 |
Why?
| Decision Making | 1 | 2007 | 290 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 107 | 0.060 |
Why?
| Epithelial Cells | 1 | 2006 | 256 | 0.060 |
Why?
| Epigenesis, Genetic | 1 | 2008 | 399 | 0.060 |
Why?
| Cell Survival | 3 | 2012 | 661 | 0.060 |
Why?
| Male | 7 | 2020 | 27350 | 0.060 |
Why?
| Cell Line, Tumor | 4 | 2009 | 1542 | 0.060 |
Why?
| Cohort Studies | 2 | 2020 | 1549 | 0.060 |
Why?
| Ultrasonography | 1 | 2006 | 479 | 0.060 |
Why?
| Base Sequence | 3 | 2010 | 732 | 0.060 |
Why?
| Prospective Studies | 2 | 2022 | 2607 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2007 | 1075 | 0.050 |
Why?
| Gene Expression Profiling | 1 | 2007 | 1138 | 0.050 |
Why?
| Yersinia pseudotuberculosis | 1 | 2001 | 5 | 0.050 |
Why?
| Yersinia Infections | 1 | 2001 | 6 | 0.050 |
Why?
| Yersinia enterocolitica | 1 | 2001 | 6 | 0.050 |
Why?
| Adolescent | 3 | 2015 | 6890 | 0.050 |
Why?
| Formaldehyde | 1 | 2020 | 49 | 0.050 |
Why?
| Oncogenes | 1 | 2020 | 63 | 0.050 |
Why?
| Animals | 6 | 2017 | 14435 | 0.050 |
Why?
| Disease Progression | 3 | 2008 | 915 | 0.050 |
Why?
| Appendicitis | 1 | 2001 | 78 | 0.050 |
Why?
| Transplantation, Heterologous | 2 | 2010 | 76 | 0.050 |
Why?
| Neoplasm Staging | 2 | 2015 | 801 | 0.040 |
Why?
| Toxicology | 1 | 1999 | 32 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2008 | 1295 | 0.040 |
Why?
| DNA Methylation | 3 | 2008 | 575 | 0.040 |
Why?
| Blotting, Western | 2 | 2012 | 685 | 0.040 |
Why?
| DNA Primers | 2 | 2010 | 225 | 0.040 |
Why?
| Paraffin Embedding | 1 | 2018 | 56 | 0.040 |
Why?
| Receptors, Progesterone | 1 | 2018 | 58 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 62 | 0.040 |
Why?
| Young Adult | 2 | 2020 | 4320 | 0.040 |
Why?
| Receptors, Estrogen | 1 | 2018 | 133 | 0.040 |
Why?
| Lymphatic System | 1 | 2017 | 15 | 0.040 |
Why?
| Methylene Blue | 1 | 2017 | 12 | 0.040 |
Why?
| Animals, Genetically Modified | 1 | 2017 | 52 | 0.040 |
Why?
| Coloring Agents | 1 | 2017 | 84 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2017 | 198 | 0.040 |
Why?
| Prognosis | 2 | 2015 | 2116 | 0.040 |
Why?
| Follow-Up Studies | 2 | 2015 | 2384 | 0.030 |
Why?
| Cost Savings | 1 | 2015 | 67 | 0.030 |
Why?
| Treatment Outcome | 1 | 2006 | 5596 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2015 | 131 | 0.030 |
Why?
| Mice, Knockout | 2 | 2008 | 941 | 0.030 |
Why?
| Apoptosis | 2 | 2012 | 1306 | 0.030 |
Why?
| Tumor Microenvironment | 1 | 2016 | 207 | 0.030 |
Why?
| Collagen | 1 | 2016 | 229 | 0.030 |
Why?
| RNA, Messenger | 2 | 2008 | 1222 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2015 | 291 | 0.030 |
Why?
| In Situ Nick-End Labeling | 1 | 2012 | 64 | 0.030 |
Why?
| Immunoprecipitation | 1 | 2012 | 73 | 0.030 |
Why?
| Staurosporine | 1 | 2009 | 14 | 0.020 |
Why?
| Deoxycytidine | 1 | 2009 | 28 | 0.020 |
Why?
| Flow Cytometry | 1 | 2012 | 548 | 0.020 |
Why?
| Cell Line | 1 | 2012 | 1166 | 0.020 |
Why?
| Drug Synergism | 1 | 2009 | 171 | 0.020 |
Why?
| Cell Adhesion | 1 | 2009 | 171 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2009 | 219 | 0.020 |
Why?
| RNA Interference | 1 | 2009 | 195 | 0.020 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 2008 | 18 | 0.020 |
Why?
| Luciferases | 1 | 2008 | 57 | 0.020 |
Why?
| Florida | 1 | 2008 | 59 | 0.020 |
Why?
| Adenoviridae | 1 | 2008 | 60 | 0.020 |
Why?
| Chromatin Immunoprecipitation | 1 | 2008 | 56 | 0.020 |
Why?
| Fluorouracil | 1 | 2008 | 61 | 0.020 |
Why?
| Histone Deacetylase 2 | 1 | 2007 | 4 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 96 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 126 | 0.020 |
Why?
| Loss of Heterozygosity | 1 | 2008 | 97 | 0.020 |
Why?
| Co-Repressor Proteins | 1 | 2007 | 18 | 0.020 |
Why?
| Transcriptional Activation | 1 | 2008 | 134 | 0.020 |
Why?
| Phosphorylation | 1 | 2009 | 609 | 0.020 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2008 | 142 | 0.020 |
Why?
| Sequence Deletion | 1 | 2007 | 101 | 0.020 |
Why?
| Estrogens | 1 | 2009 | 246 | 0.020 |
Why?
| Molecular Chaperones | 1 | 2007 | 65 | 0.020 |
Why?
| Histone Deacetylases | 1 | 2007 | 48 | 0.020 |
Why?
| Transfection | 1 | 2008 | 410 | 0.020 |
Why?
| Ultrasonography, Mammary | 1 | 2007 | 61 | 0.020 |
Why?
| Tumor Cells, Cultured | 1 | 2007 | 483 | 0.020 |
Why?
| Cystatin M | 1 | 2006 | 21 | 0.020 |
Why?
| 5' Untranslated Regions | 1 | 2006 | 33 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2008 | 514 | 0.020 |
Why?
| Chromatin | 1 | 2007 | 155 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 55 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2009 | 456 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2008 | 419 | 0.020 |
Why?
| Carcinoma | 1 | 2007 | 153 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2008 | 996 | 0.020 |
Why?
| Repressor Proteins | 1 | 2007 | 167 | 0.020 |
Why?
| Down-Regulation | 1 | 2007 | 392 | 0.020 |
Why?
| Wound Healing | 1 | 2007 | 231 | 0.020 |
Why?
| Cesarean Section | 1 | 2007 | 178 | 0.020 |
Why?
| Protein Binding | 1 | 2007 | 743 | 0.020 |
Why?
| Survival Rate | 1 | 2008 | 955 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 867 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2005 | 318 | 0.020 |
Why?
| Neoplasm Recurrence, Local | 1 | 2008 | 643 | 0.020 |
Why?
| Cells, Cultured | 1 | 2008 | 1755 | 0.020 |
Why?
| Pregnancy Complications | 1 | 2007 | 387 | 0.010 |
Why?
| Child | 2 | 2008 | 7312 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2007 | 1210 | 0.010 |
Why?
| Appendix | 1 | 2001 | 29 | 0.010 |
Why?
| DNA, Bacterial | 1 | 2001 | 172 | 0.010 |
Why?
| Infant, Newborn | 1 | 2008 | 2901 | 0.010 |
Why?
| Occupational Medicine | 1 | 1999 | 4 | 0.010 |
Why?
| History, Ancient | 1 | 1999 | 9 | 0.010 |
Why?
| Environmental Medicine | 1 | 1999 | 2 | 0.010 |
Why?
| Forensic Medicine | 1 | 1999 | 11 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1603 | 0.010 |
Why?
| History, 19th Century | 1 | 1999 | 35 | 0.010 |
Why?
| Pregnancy | 1 | 2007 | 2614 | 0.010 |
Why?
| Infant | 1 | 2008 | 3797 | 0.010 |
Why?
| History, 20th Century | 1 | 1999 | 115 | 0.010 |
Why?
| Child, Preschool | 1 | 2008 | 4132 | 0.010 |
Why?
| Risk Factors | 1 | 2008 | 3936 | 0.010 |
Why?
|
|
Massoll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|